Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab

Anti-vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (DME) favorably affects diabetic retinopathy (DR) improvement and worsening. It is unknown whether these effects differ across anti-VEGF agents. To compare changes in DR severity during aflibercept, bevacizumab, o...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	JAMA ophthalmology Ročník 135; číslo 6; s. 558
Hlavní autoři:	Bressler, Susan B, Liu, Danni, Glassman, Adam R, Blodi, Barbara A, Castellarin, Alessandro A, Jampol, Lee M, Kaufman, Paul L, Melia, Michele, Singh, Harinderjit, Wells, John A
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.06.2017
Témata:	Angiogenesis Inhibitors - administration & dosage Bevacizumab - administration & dosage Diabetic Retinopathy - diagnosis Diabetic Retinopathy - drug therapy Diabetic Retinopathy - physiopathology Disease Progression Dose-Response Relationship, Drug Follow-Up Studies Humans Intravitreal Injections Ranibizumab - administration & dosage Receptors, Vascular Endothelial Growth Factor - administration & dosage Recombinant Fusion Proteins - administration & dosage Retina - pathology Retrospective Studies Severity of Illness Index Time Factors Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity
ISSN:	2168-6173, 2168-6173
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!